Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring <scp><i>BRAF</i></scp> mutations in the <scp>L</scp>ung <scp>C</scp>ancer <scp>M</scp>utation <scp>C</scp>onsortium

Villaruz, Liza C.; Socinski, Mark A.; Abberbock, Shira; Berry, Lynne D.; Johnson, Bruce E.; Kwiatkowski, David J.; Iafrate, A. John; Varella‐Garcia, Marileila; Franklin, Wilbur A.; Camidge, D. Ross; Sequist, Lecia V.; Haura, Eric B.; Ladanyi, M.; Kurland, Brenda F.; Kugler, Kelly; Minna, John D.; Bunn, Paul A.; Kris, Mark G.

doi:10.1002/cncr.29042

Cited by 109 publications

(117 citation statements)

References 29 publications

Supporting

Mentioning

111

Contrasting

Order By: Relevance

“…BRAF gene mutation was not detected in the present study. This mutation could have an activating character with a positive response to MAPK kinase (MEK) inhibitor (Vemurafenib) treatment, nevertheless, it decreases response to TKI inhibitor treatment in lung carcinomas with EGFR gene mutations (17), and according to certain studies, BRAF mutation (V600E) represents an unfavorable prognostic factor (18,19). Due to these reasons, it is necessary to observe mutational changes in the whole EGFR ras/raf/MAPK signaling pathway (20).…”

Section: Discussionmentioning

confidence: 99%

Molecular pathological predictive diagnostics in a patient with non‑small cell lung cancer treated with crizotinib therapy: A case report

et al. 2017

View full text Add to dashboard Cite

Abstract. Lung cancer is one of the most common malignant cancers in the Czech Republic in men, with the highest mortality rate of all the malignant diseases. The development of biological treatment enables study into novel personalized treatment options. This type of treatment is usually of high quality, and is often demanding of predictive and biopsy diagnostics, which is dependent on the quality of the collected material and close cooperation among particular departments. The present study describes the complete biopsy and predictive examinations performed in a male patient with lung adenocarcinoma, with an emphasis on the logistics of the whole process and the application of the tyrosine kinase inhibitors, crizotinib and LDK378. The patient experienced a long overall survival time of 28 months from diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Molecular pathological predictive diagnostics in a patient with non‑small cell lung cancer treated with crizotinib therapy: A case report

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Somatic mutations in BRAF are observed in 1-4% of NSCLC cases [Ali et al 2015;Brustugun et al 2014;Cardarella et al 2013;Ilie et al 2013;Kinno et al 2014;Litvak et al 2014;Luk et al 2015;Marchetti et al 2011;Paik et al 2011;Tissot et al 2016;Villaruz et al 2015]. Lung adenocarcinoma is known for its high rate of somatic mutations and genomic rearrangements, challenging identification of driver gene alterations because of a large burden of passenger events per tumor genome [Ding et al 2008;Govindan et al 2012;Imielinski et al 2012].…”

Section: Distribution Of Braf Aberrations In Lung Cancermentioning

confidence: 99%

“…the percentage of smoking patients varies between 57-100%, with smoking being more prevalent in the population with non-V600E BRAF mutations [Brustugun et al 2014;Cardarella et al 2013;Ilie et al 2013;Litvak et al 2014;Luk et al 2015;Marchetti et al 2011;Paik et al 2011;Tissot et al 2016;Villaruz et al 2015].…”

Section: Distribution Of Braf Aberrations In Lung Cancermentioning

confidence: 99%

“…In small series no differences were seen in the prognosis of BRAF-mutated and BRAF WT patients treated with platinum-doublet chemotherapy [Cardarella et al 2013;Tissot et al 2016;Villaruz et al 2015]. In a small retrospective study, the value of BRAF inhibitor rechallenge was evaluated in patients with BRAF V600-positive melanoma.…”

Section: Other Systemic Therapiesmentioning

confidence: 99%

“…BRAF mutations, for example, can be seen in 50% of melanoma cases, but only in 1-4% of NSCLC cases [Ali et al 2015;Brustugun et al 2014;Cardarella et al 2013;Ilie et al 2013;Kinno et al 2014;Litvak et al 2014;Luk et al 2015;Marchetti et al 2011;Paik et al 2011;Tissot et al 2016;Villaruz et al 2015]. In this review we will focus on BRAF alterations and the therapeutic approach for patients with NSCLC whose tumor harbors a genetic aberration in the BRAF gene.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications

Langen

Smit

2016

Ther Adv Med Oncol

View full text Add to dashboard Cite

Lung adenocarcinoma is known for its high rate of somatic mutations and genomic rearrangements. The identification of epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements that sensitize tumors to specific drugs has changed the therapeutic approach and prognosis in these molecularly-defined subgroups. Several other key genetic alterations have been identified, of which BRAF mutations are found in 4% of non-small cell lung cancer (NSCLC) cases. Targeted drugs against BRAF and downstream MEK were recently approved for the treatment of BRAF-positive melanoma and have entered clinical evaluation in NSCLC. In this review we discuss the latest evidence on the treatment of BRAF-mutated NSCLC, including tumor biology, targeted treatment with BRAF and MEK inhibitors, therapeutic resistance and strategies to overcome resistance.

show abstract

Clinicopathologic characteristics and outcomes of Chinese patients with non‐small‐cell lung cancer and BRAF mutation

et al. 2017

View full text Add to dashboard Cite

BRAF mutation is one of the important driver oncogene in non‐small‐cell lung cancer (NSCLC). Data on Chinese patients with BRAF‐mutant NSCLC are inadequate. Hence, we conducted this study to investigate the clinicopathologic features and outcomes of Chinese patients with NSCLC and BRAF mutations. We identified patients with BRAF‐mutant NSCLC between January 2012 and April 2016. Patient characteristics and treatment outcomes were analyzed. In total, 1680 patients were included. Twenty‐eight (1.7%) patients harbored BRAF mutations. Compared to patients with non‐BRAF mutation, patients with BRAF mutations were associated with adenocarcinomas (89.3% vs. 70.6%, P = 0.048) and never smokers (78.6% vs. 56.7%, P = 0.019). There were no significant differences in the age, gender distribution, metastasis, or stage at first diagnosis between two groups. Response rates and progression‐free survival (PFS) were similar between patient with BRAF mutations and EGFR (5.6 vs. 5.8 months; P = 0.277) or KRAS (5.6 vs. 4.7 months; P = 0.741) mutations to first‐line chemotherapy. Compared to patients with non‐V600E mutations, patients with V600E‐mutated tumors had a shorter PFS to first‐line chemotherapy, although this did not reach statistical significance (5.2 vs. 6.4 months; P = 0.561). In multivariate analyses, only ECOG PS remained the independent predictor of overall survival (HR = 0.208; P = 0.004). In conclusion, BRAF mutation in Chinese patients with NSCLC was rare. BRAF mutation is more likely to be associated with adenocarcinoma and never smokers. BRAF mutations are not associated with enhanced chemosensitivity and novel and effective drugs inhibiting the BRAF pathway are in urgent need.

show abstract

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium

Cited by 109 publications

References 29 publications

Molecular pathological predictive diagnostics in a patient with non‑small cell lung cancer treated with crizotinib therapy: A case report

Molecular pathological predictive diagnostics in a patient with non‑small cell lung cancer treated with crizotinib therapy: A case report

Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications

Clinicopathologic characteristics and outcomes of Chinese patients with non‐small‐cell lung cancer and BRAF mutation

Contact Info

Product

Resources

About